The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
From the blog
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)
The objective of the study is to induce a meaningful progression-free survival benefit in patients with Malign Pleural Mesothelioma (MPM) after progression on first line standard platinum doublet chemotherapy, by treating with nivolumab and ipilimumab with or without UV1 vaccine.
HMPL-453 in Advanced Malignant Mesothelioma
This is a phase II, single arm, multicenter and open-label study to evaluate the efficacy, safety and pharmacokinetic of HMPL-453 in patient with advanced Malignant Mesothelioma
Doctors Will Soon be Able to Test if Surgery is Safe for Mesothelioma Patients
Doctors could soon know if surgery is the best option for mesothelioma patients. Surgery is one of the most effective ways to improve patients’ lives. The problem is that undergoing surgery is very stressful on people’s bodies, especially when they have cancer. It is better to know if surgery can[…]
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (PEMMELA)
There is no standard second line treatment in malignant pleural mesothelioma (MPM). Pembrolizumab has shown to be active in in small phase II studies in MPM. Its activity however, is limited, with a response rate up to 20%. So, there is a need for new treatment combinations with drugs that might exhibit a synergistic interaction with pembrolizumab.
2019 Mesothelioma Treatments in Review
There have been many different advances in medicine benefitting mesothelioma patients, and over the course of 2019, different clinical trials have shown that there is still hope for them. One of the clinical trials in 2019 studied Nivolumab, also called Opdivo, as a first- and second-line treatment for mesothelioma. The[…]
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
Different Mesothelioma and Cancer Support Groups
Many times, when people are diagnosed with mesothelioma, they don’t know where to turn. Such a devastating illness can be very isolating and can even cause depression. It might be hard to handle a mesothelioma diagnosis, but people can have hope and support from around the country and even the[…]
Oncolytic Viruses with Standard Chemotherapy can Help Mesothelioma Patients
Mesothelioma is a cancer with a poor prognosis. People who are diagnosed do not normally have many options, but can at least have hope because of different clinical trials. Clinical trials can help find new treatments and medications to better help mesothelioma sufferers. A clinical trial in Oslo, Norway is[…]
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors.
Skip to content